摘要
支气管哮喘(哮喘)是全球常见的慢性呼吸系统疾病,具有高度的异质性,其主要特征为呼吸症状既往史和可逆性呼气气流限制。目前对于哮喘的分型、诊断和管理都仍在探索中。作为后基因组学代表性技术,代谢组学能够广泛分析样本中内源和外源性的低相对分子质量代谢物(<1500)。因哮喘异质性高,在哮喘的基础研究中有独特优势,代谢组学能够更敏感地捕捉哮喘患者体内的代谢波动和病理变化。本文综述了2013年以来,重点综述了2016年之后基于代谢组学在哮喘方面的研究进展,其中包括对哮喘诊断、分型、评估和应用药物。
Bronchial asthma(asthma)is a global common chronic respiratory disease which is highly heterogeneous.It is usually characterized by previous history of respiratory symptoms and variable expiratory airflow limitation.Now it still remains explorable of the phenotypes,identification,and management of the disease.As a representative technology in the post-genomics era,metabolomics could universally analyze the endogenous and exogenous low-molecular-weight metabolites(<1500).Because of the high heterogeneity of asthma,the methods of metabolomics could capture the metabolite fluctuation and its pathology in vivo more sensitively.Thus,the methods of metabolomics have their unique advantages in researches about asthma.This review includes the research progress of metabolomics since 2013,especially since 2016 in the aspect of diagnosis,phenotypes,assessment,and drugs.
作者
王雪婷
顾问
Wang Xueting;Gu Wen(Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Deparment of Respiratory Medicine,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China)
出处
《国际呼吸杂志》
2020年第11期847-852,共6页
International Journal of Respiration
基金
国家自然科学基金(81770023)
上海市科学技术委员会科研计划项目(17ZR1418400)。
关键词
代谢
哮喘
质谱法
Metabolism
Asthma
Mass spectrometry
